[{"orgOrder":0,"company":"Pathogen and Microbiome Institute ","sponsor":"Oncology Venture","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Stenoparib","moa":"PARP","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Pathogen and Microbiome Institute ","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Pathogen and Microbiome Institute \/ Oncology Venture","highestDevelopmentStatusID":"4","companyTruncated":"Pathogen and Microbiome Institute \/ Oncology Venture"},{"orgOrder":0,"company":"Oncology Venture","sponsor":"2X Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Stenoparib","moa":"PARP","graph1":"Oncology","graph2":"Phase II","graph3":"Oncology Venture","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Oncology Venture \/ 2X Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Oncology Venture \/ 2X Oncology"},{"orgOrder":0,"company":"Oncology Venture","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Stenoparib","moa":"PARP1","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Oncology Venture","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Oncology Venture \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Oncology Venture \/ Not Applicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Allarity Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Stenoparib","moa":"PARP1","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Eisai \/ Allarity Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Eisai \/ Allarity Therapeutics"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Stenoparib","moa":"PARP1","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Allarity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Allarity Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Stenoparib","moa":"PARP1","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Allarity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Allarity Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Stenoparib","moa":"PARP1","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Allarity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Allarity Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Viroclinics Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Stenoparib","moa":"PARP1","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Allarity Therapeutics \/ Viroclinics","highestDevelopmentStatusID":"4","companyTruncated":"Allarity Therapeutics \/ Viroclinics"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dovitinib","moa":"Pan-TKI","graph1":"Oncology","graph2":"Phase III","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allarity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allarity Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Dovitinib","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allarity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Allarity Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Stenoparib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Allarity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Allarity Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Stenoparib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allarity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Allarity Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Stenoparib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allarity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Allarity Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Stenoparib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allarity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Allarity Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Stenoparib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Allarity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Allarity Therapeutics \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Stenoparib

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : 2X-121 (stenoparib) is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and Tankyrase 1 and 2. It is being evaluated for the treatment of advanced recurrent ovarian cancer.

                          Brand Name : 2X-121

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 25, 2024

                          Lead Product(s) : Stenoparib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : 2X-121 (stenoparib) is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and Tankyrase 1 and 2. It is being evaluated for the treatment of advanced recurrent ovarian cancer.

                          Brand Name : 2X-121

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 02, 2024

                          Lead Product(s) : Stenoparib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : 2X-121 (stenoparib) is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and Tankyrase 1 and 2. It is being evaluated for the treatment of advanced recurrent ovarian cancer.

                          Brand Name : 2X-121

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 27, 2024

                          Lead Product(s) : Stenoparib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : 2X-121 (stenoparib) is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and Tankyrase 1 and 2. It is being evaluated for the treatment of advanced recurrent ovarian cancer.

                          Brand Name : 2X-121

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          December 05, 2023

                          Lead Product(s) : Stenoparib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : 2X-121 (stenoparib) is a PARP inhibitor in Phase 2 development for ovarian cancer and in Phase 1 development for advanced solid tumors in a combination treatment with dovitinib, a pan-tyrosine kinase inhibitor that has previously been developed through P...

                          Brand Name : 2X-121

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 28, 2023

                          Lead Product(s) : Stenoparib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Stenoparib is a dual-targeted inhibitor of PARP 1, 2 and tankyrase 1, 2 where dovitinib is a pan-tyrosine kinase inhibitor. The combination may increase the chances of cancer apoptosis and providing synergistic, enhanced antitumor activity.

                          Brand Name : TKI258

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 20, 2023

                          Lead Product(s) : Dovitinib,Stenoparib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The DRP® platform has proven its ability to provide a statistically significant prediction of clinical outcome from drug treatment in cancer patients in 37 out of 47 clinical studies that were examined including ongoing, prospective Phase 2 trials of St...

                          Brand Name : TKI258

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 02, 2022

                          Lead Product(s) : Dovitinib,Stenoparib

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The additional pre-clinical results show that stenoparib demonstrated antiviral activity inhibiting the delta variant in a dose-dependent manner in Vero E6 cells. The delta variant used for the experiments carries an additional deletion in ORF7a, a rapid...

                          Brand Name : 2X-121

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 11, 2021

                          Lead Product(s) : Stenoparib

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Viroclinics Biosciences

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Currently, the delta variant (lineage B.1.617.2) has become the dominant strain of SARS-CoV-2, and near-term tests of stenoparib against this variant are being initiated by Allarity.

                          Brand Name : 2X-121

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 05, 2021

                          Lead Product(s) : Stenoparib

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The current and planned in-vitro studies, focusing on SARS-CoV-2 lineage B.1.1.7 and B.1.351, follow previous positive pre-clinical test results with stenoparib as a treatment of SARS-CoV-2 published in the peer-review journal mBio.

                          Brand Name : 2X-121

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          February 24, 2021

                          Lead Product(s) : Stenoparib

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank